London, Ontario – TheNewswire - September 8, 2025 - Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced it will be participating in the upcoming H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Jonathan Rigby, Sernova’s President and CEO, will provide a company overview in a virtual ...